UPLOAD Filing
ALNYLAM PHARMACEUTICALS, INC.
Date: June 17, 2025 · CIK: 0001178670 · Accession: 0000000000-25-006335
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36407
Letter
Re: Alnylam Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 13, 2025 File No. 001-36407 Dear Gisele Dion:
June 17, 2025
Gisele Dion Chief Accounting Officer Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri A. Termeer Square Cambridge, MA 02142
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 17, 2025 Gisele Dion Chief Accounting Officer Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri A. Termeer Square Cambridge, MA 02142 Re: Alnylam Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 13, 2025 File No. 001-36407 Dear Gisele Dion: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>